ABSTRACT
BACKGROUND: HIV and tuberculosis (TB) are commonly associated. Identifying latent and asymptomatic tuberculosis infection in HIV-positive patients is important in preventing death and morbidity associated with active TB. METHODS: Cross-sectional study of one time use of an interferon-gamma release assay (T-SPOT.TB - immunospot) to detect tuberculosis infection in patients in a UK inner city HIV clinic with a large sub-Saharan population. RESULTS: 542 patient samples from 520 patients who disclosed their symptoms of TB were tested. Median follow-up was 35 months (range 27-69). More than half (55%) originated from countries with medium or high tuberculosis burden and 57% were women. Antiretroviral therapy was used by 67%; median CD4 count at test was 458 cells/µl. A negative test was found in 452 samples and an indeterminate results in 40 (7.4%) but neither were associated with a low CD4 count. A positive test was found in 10% (50/502) individuals. All patients with positive tests were referred to the TB specialist, 47 (94%) had a chest radiograph and 46 (92%) attended the TB clinic. Two had culture-positive TB and a third individual with features of active TB was treated. 40 started and 38 completed preventive treatment. One patient who completed preventive treatment with isoniazid monotherapy subsequently developed isoniazid-resistant pulmonary tuberculosis. No patient with a negative test has developed TB. CONCLUSIONS: We found an overall prevalence of latent TB infection of 10% through screening for TB in those with HIV infection and without symptoms, and a further 1% with active disease, a yield greater than typically found in contact tracing. Acceptability of preventive treatment was high with 85% of those with latent TB infection eventually completing their TB chemotherapy regimens. IGRA-based TB screening among HIV-infected individuals was feasible in the clinical setting and assisted with appropriate management (including preventive treatment and therapy for active disease). Follow-up of TB incidence in this group is needed to assess the long-term effects of preventive treatment.
Subject(s)
HIV Infections/complications , Latent Tuberculosis/epidemiology , Adolescent , Adult , Aged , Asymptomatic Diseases , Cross-Sectional Studies , Female , Humans , Interferon-gamma Release Tests/methods , Male , Middle Aged , Prevalence , United Kingdom/epidemiology , Urban Population , Young AdultABSTRACT
OBJECTIVES: To determine the diagnostic value of a blood interferon-gamma release assay in suspected active tuberculosis (TB). METHODS: 136 subjects with suspected pulmonary TB (pTB) at a single London centre with intermediate TB incidence, were clinically graded into low (<25%), medium, or high (>75%) likelihood of active pTB and then tested by T-SPOT®.TB assay. The diagnosis was confirmed by culture (n = 33), treatment response (n = 13) or a firm alternative diagnosis (n = 90). RESULTS: Overall, the T-SPOT.TB sensitivity was 74% (95% confidence intervals 60-84%), positive predictive value (PPV) 56% (43-68%), negative predictive value (NPV) 83% (71-90%), positive likelihood ratio (PLR) 1.75 and negative likelihood ratio (NLR) 0.45. Results for high pTB likelihood subjects: PPV 100%, NPV 25% (7-60%), PLR >69, NLR 0.31. Results for intermediate pTB likelihood subjects: PPV 67% (41-85%), NPV 88% (65-96%), PLR 2.39, NLR 0.26. Results for low pTB likelihood subjects: PPV 15% (6-34%), NPV 92% (79-97%), PLR 1.23, NLR 0.80. False negatives occurred in 24% of cases of active tuberculosis (4 smear and culture-positive, 3 smear negative and culture-positive, and 4 culture negative). CONCLUSIONS: The predictive values and likelihood ratios show the T-SPOT.TB test does not assist in confidently confirming or excluding active TB, regardless of the pre-test probability of disease.
Subject(s)
Clinical Laboratory Techniques/methods , Tuberculosis/diagnosis , Bayes Theorem , False Negative Reactions , Female , Humans , Immunoassay/methods , Interferon-gamma/metabolism , London , Male , Predictive Value of Tests , Prospective Studies , Sensitivity and SpecificityABSTRACT
BACKGROUND: The QuantiFERON® test (QFT) is a diagnostic tool for active and latent tuberculosis (TB) infections. High rates of positivity to QuantiFERON® have been demonstrated in patients with chronic kidney disease (CKD) and diabetic patients. We performed a pilot study to investigate if QFT positivity in diabetic CKD patients predicted the rate of renal function decline. METHODS: QFT was performed in 38 diabetic patients with CKD 4-5 not on dialysis. The rate of decline in estimated glomerular filtration rate (eGFR) was calculated. RESULTS: 18/38 patients had a positive QFT. Patients with a positive QFT had a steeper decline in eGFR, compared with patients with a negative QFT. Ethnicity (a marker of risk of previous TB exposure), urine protein/creatinine ratio, use of ACE inhibitors/angiotensin II receptor blockers and statins, serum C-reactive protein, vitamin D levels, HbA1c concentration and presenting GFR did not differ significantly. CONCLUSIONS: The finding in this small cohort needs to be replicated in a larger study because our study is susceptible to both type I and type II statistical error. We found that QFT positivity was associated with a more rapid rate of decline in GFR, but this association may be coincidental (with the difference in decline attributed to differences in the blood pressure or proteinuria of the two groups). Moreover, an association does not necessarily mean causality, although it would be interesting to speculate if we are identifying patients with latent TB who have an active interstitial nephritis. Another intriguing possibility is that this assay identifies patients with an immunological phenotype that predisposes to eGFR loss.
Subject(s)
Antigens, Bacterial/blood , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/physiopathology , Glomerular Filtration Rate/physiology , Interferon-gamma/metabolism , Aged , Cohort Studies , Diabetic Nephropathies/diagnosis , Female , Follow-Up Studies , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/metabolism , Male , Middle Aged , Pilot Projects , Predictive Value of Tests , Prospective StudiesABSTRACT
Matrix metalloproteinases (MMP) can degrade all components of pulmonary extracellular matrix. Mycobacterium tuberculosis induces production of a number of these enzymes by human macrophages, and these are implicated in the pathogenesis of pulmonary cavitation in tuberculosis. The active metabolite of vitamin D, 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)], has previously been reported to inhibit secretion of MMP-9 in human monocytes (MN), but its influence on the secretion and gene expression of MMP and tissue inhibitors of MMP (TIMP) in M. tuberculosis-infected cells has not previously been investigated. We therefore determined the effects of 1alpha,25(OH)(2)D(3) on expression, secretion and activity of a number of MMP and TIMP in M. tuberculosis-infected human leucocytes; we also investigated the effect of 1alpha,25(OH)(2)D(3) on the secretion of interleukin-10 (IL-10) and prostaglandin E(2) (PGE(2)), both transcriptional regulators of MMP expression. We found that M. tuberculosis induced expression of MMP-1, MMP-7 and MMP-10 in MN and MMP-1 and MMP-10 in peripheral blood mononuclear cells (PBMC). 1alpha,25(OH)(2)D(3) significantly attenuated M. tuberculosis-induced increases in expression of MMP-7 and MMP-10, and suppressed secretion of MMP-7 by M. tuberculosis-infected PBMC. MMP-9 gene expression, secretion and activity were significantly inhibited by 1alpha,25(OH)(2)D(3) irrespective of infection. In contrast, the effects of 1alpha,25(OH)(2)D(3) on the expression of TIMP-1, TIMP-2 and TIMP-3 and secretion of TIMP-1 and TIMP-2 were small and variable. 1alpha,25(OH)(2)D(3) also induced secretion of IL-10 and PGE(2) from M. tuberculosis-infected PBMC. These findings represent a novel immunomodulatory role for 1alpha,25(OH)(2)D(3) in M. tuberculosis infection.